Virtus Biotech ETF
BBP
19 hedge funds and large institutions have $11.9M invested in Virtus Biotech ETF in 2018 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
6% more funds holding
Funds holding: 18 → 19 (+1)
0.06% less ownership
Funds ownership: 33.92% → 33.86% (-0.06%)
9% less capital invested
Capital invested by funds: $13.1M → $11.9M (-$1.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$437K |
| 2 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$294K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$126K |
| 4 |
SMG
Smart Money Group
Eastland,
Texas
|
+$76.3K |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
+$66.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.18M |
| 2 |
Jane Street
New York
|
-$1.04M |
| 3 |
LPL Financial
San Diego,
California
|
-$121K |
| 4 |
CA
Calton & Associates
Tampa,
Florida
|
-$91K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$23K |
BBP Hedge Fund Activity: Q1 2018 in Review
19 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech ETF (BBP) for Q1 2018, worth a combined $11.9M — down 9.2% from $13.1M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BBP positions and 1 closed out — a net gain of 1 holder — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Virtu Financial, adding an estimated $437K. The largest seller was Royal Bank of Canada, cutting an estimated $1.18M.
- 19 institutional investors held Virtus Biotech ETF (BBP) as of Q1 2018, up from 18 in Q4 2017.
- Funds reported $11.9M of Virtus Biotech ETF stock for Q1 2018, down 9.2% quarter-over-quarter.
- 2 funds opened new Virtus Biotech ETF positions in Q1 2018 and 1 closed out, a net change of +1 holder.
- The largest Virtus Biotech ETF buyer in Q1 2018 was Virtu Financial, an estimated $437K added.
- The largest Virtus Biotech ETF seller in Q1 2018 was Royal Bank of Canada, an estimated $1.18M sold.
Based on aggregated 13F filings for Q1 2018.